Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof. R1 and R2 are independently hydrogen, fluorine or alkyl; R3 is aryl or heteroaryl R4 is alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; m is an integer of 0 to 2; and n is an integer of 1 to 3. The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.

Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof for use as inhibitors of cyclin dependent kinases, wherein:X is O, S(O).sub.m ;Y is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl;R.sub.1 is hydrogen or lower alkyl;R.sub.2 is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, --O-alkyl, --O-aryl, --NR.sub.4 R.sub.5 ;R.sub.3 is hydrogen or lower alkyl;R.sub.4 is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, --O-alkyl, --O-aryl;R.sub.5 is hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, --O-alkyl, --O-aryl; andm is 0, 1 or 2.

Abstract: Compounds of the formula ##STR1## and pharmaceuticaly acceptable salts thereof. As used in formula I, and throughout the specification, the symbols have the following meanings:R.sub.1 and R.sub.2 are independently hydrogen, fluorine or alkyl;R.sub.3 is aryl or heteroarylR.sub.4 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; orCO-alkyl,CONH-alkyl,COO-alkyl,SO.sub.2 -alkyl,C(NCN)NH-alkyl,C(NNO.sub.2)NH-alkyl,C(NH)NH-alkyl,C(NH)NHCO-alkyl,C(NOR.sub.6)NH-alkyl,R.sub.5 is hydrogen or alkyl;R.sub.6 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylakyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;m is an integer of 0 to 2; andn is an integer of 1 to 3.The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis.

Abstract: Novel peptide and peptide mimetic ligands which act as inhibitors of p34.sup.cdc2 kinase, p33.sup.cdk2 kinase and human papillomavirus transforming protein E7 (HPV E7) are disclosed. The inhibitors are derived from the binding domains of a retinoblastoma tumor suppressor protein (Rb), p107 and a cyclin.